Benzinga | Feb 16, 2021 01:29PM EST

Clene To Start Testing CNM-ZnAg In COVID-19 Patients In Brazil

* Regulatory authorities in Brazil signed off Clene Inc's (NASDAQ: CLNN) Phase 2 study evaluating CNM-ZnAg liquid solution in acutely symptomatic, non-hospitalized COVID-19 patients. CNM-ZnAg is a proprietary zinc-silver ionic solution.

* The 276-subject trial's primary endpoint will evaluate the rate of decreased hospitalizations at day 28, with secondary endpoints assessing time to symptom resolution.

* Enrollment will complete in mid-2021, with results expected in the second half of 2021.

* Price Action: CLNN gained 13.2% at $14.14 in market trading hours on the last check Tuesday.